Statera Biopharma, Inc. (STAB)

USD 0.0

(0.0%)

Total Liabilities Summary of Statera Biopharma, Inc.

  • Statera Biopharma, Inc.'s latest annual total liabilities in 2021 was 22.67 Million USD , up 383.38% from previous year.
  • Statera Biopharma, Inc.'s latest quarterly total liabilities in 2022 Q3 was 22.91 Million USD , up 11.99% from previous quarter.
  • Statera Biopharma, Inc. reported annual total liabilities of 4.69 Million USD in 2020, up 11.39% from previous year.
  • Statera Biopharma, Inc. reported annual total liabilities of 4.21 Million USD in 2019, up 357.58% from previous year.
  • Statera Biopharma, Inc. reported quarterly total liabilities of 15.94 Million USD for 2022 Q1, down -29.69% from previous quarter.
  • Statera Biopharma, Inc. reported quarterly total liabilities of 20.46 Million USD for 2022 Q2, up 28.34% from previous quarter.

Annual Total Liabilities Chart of Statera Biopharma, Inc. (2021 - 2006)

Historical Annual Total Liabilities of Statera Biopharma, Inc. (2021 - 2006)

Year Total Liabilities Total Liabilities Growth
2021 22.67 Million USD 383.38%
2020 4.69 Million USD 11.39%
2019 4.21 Million USD 357.58%
2018 920.38 Thousand USD -58.56%
2017 2.22 Million USD -28.57%
2016 3.1 Million USD -46.79%
2015 5.84 Million USD -99.87%
2014 4.55 Billion USD -65.29%
2013 13.11 Billion USD 13.8%
2012 11.52 Billion USD 0.0%
2011 - USD -100.0%
2010 35.58 Billion USD 166.46%
2009 13.35 Billion USD 220.38%
2008 4.16 Billion USD 129043.71%
2007 3.22 Million USD 291.99%
2006 823.37 Thousand USD 0.0%

Peer Total Liabilities Comparison of Statera Biopharma, Inc.

Name Total Liabilities Total Liabilities Difference
America Great Health 4.82 Million USD -369.982%
Ampio Pharmaceuticals, Inc. 2.37 Million USD -854.396%
Aridis Pharmaceuticals, Inc. 38.92 Million USD 41.746%
Biora Therapeutics, Inc. 132.63 Million USD 82.903%
Bio-Path Holdings, Inc. 2.77 Million USD -715.993%
Better Therapeutics, Inc. 23.84 Million USD 4.889%
Calithera Biosciences, Inc. 8.28 Million USD -173.738%
Comera Life Sciences Holdings, Inc. 9.97 Million USD -127.351%
Gene Biotherapeutics, Inc. - USD -Infinity%
eFFECTOR Therapeutics, Inc. 26.33 Million USD 13.905%
Eloxx Pharmaceuticals, Inc. 31.78 Million USD 28.652%
Evelo Biosciences, Inc. 69.43 Million USD 67.341%
Evolutionary Genomics, Inc. 7.94 Million USD -185.397%
Finch Therapeutics Group, Inc. 48.11 Million USD 52.866%
Galera Therapeutics, Inc. 157.32 Million USD 85.586%
Innovation1 Biotech Inc. 3.5 Million USD -546.798%
Kiromic BioPharma, Inc. 21.28 Million USD -6.513%
Molecular Templates, Inc. 31.17 Million USD 27.251%
Navidea Biopharmaceuticals, Inc. 12.51 Million USD -81.195%
NexImmune, Inc. 5.08 Million USD -346.015%
Orgenesis Inc. 35.53 Million USD 36.186%
Panbela Therapeutics, Inc. 16.51 Million USD -37.333%
Point of Care Nano-Technology, Inc. 266.41 Thousand USD -8411.735%
PaxMedica, Inc. Common Stock 2.29 Million USD -887.938%
Scopus BioPharma Inc. 7.45 Million USD -204.201%
Sorrento Therapeutics, Inc. 494.5 Million USD 95.414%
TRACON Pharmaceuticals, Inc. 10.91 Million USD -107.774%
Trevena, Inc. 48.26 Million USD 53.014%
Vaxxinity, Inc. 30.94 Million USD 26.718%
Vaccinex, Inc. 5.94 Million USD -281.63%
Vicapsys Life Sciences, Inc. 1.96 Million USD -1052.062%
Viracta Therapeutics, Inc. 38.37 Million USD 40.905%
ZIVO Bioscience, Inc. 2.76 Million USD -721.147%